Condition: Solid Tumor · Colorectal Cancer (CRC) · Squamous Cell Carcinoma of Head and Neck · Sponsor: One-carbon Therapeutics AB
This is a first in human, multi-center, open-label, dosage escalation study to determine the recommended dose range of TH9619 in subjects with advanced cancer.
This description comes directly from the study's public registry record.
Victoria Moody · +46708555182 · victoria.moody@one-carbon.com
Always discuss trial participation with your own doctor first.
| Institut Gustave Roussy | Villejuif, France | Recruiting |
| Vall D Hebron Institute Of Oncology | Barcelona, Spain | Recruiting |
| Hospital Universitario Fundacion Jimenez Diaz | Madrid, Spain | Recruiting |
| Newcastle University | Newcastle upon Tyne, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07151040